Basic Information
| LncRNA/CircRNA Name | THOR |
| Synonyms | Lnc-THOR, ENSG00000226856 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | tongue squamous cell carcinoma |
| ICD-0-3 | C02 |
| Methods | qPCR, Western blot, in vitro knockdown, RIP |
| Sample | Tca-8113 and Cal-27 cells, tongue cancer and adjacent noncancerous tongue tissues |
| Expression Pattern | up-regulated |
| Function Description | THOR and IGF2BP1 were dramatically upregulated in TSCC tissues. The expression of THOR is positively correlated with IGF2BP1 mRNA level. THOR mediated IGF2 expression via interacting with IGF2BP1, and affected the downstream MEK-ERK signaling pathway to regulate TSCC cells proliferation. THOR/IGF2BP1/IGF2-MEK-ERK axis regulated the proliferation of TSCC cells, implying that THOR would be a promising therapeutic target for TSCC patients. |
| Pubmed ID | 31220513 |
| Year | 2019 |
| Title | LncRNA THOR promotes tongue squamous cell carcinomas by stabilizing IGF2BP1 downstream targets |
External Links
| Links for THOR | GenBank HGNC NONCODE |
| Links for tongue squamous cell carcinoma | OMIM COSMIC |